Yes, the studies are conflicting, but in the REAL world Hydroxychloroquine with Zinc and either Zithromax or Azithromycin are getting far better clinical results than the average.
These frontline health workers are now staging a revolt, in the last few days SRC has posted links about the lawsuit from the AAPS, the press conference on the Hill and now this, physicians going straight to the White House to try and get access to the tools they need to save their patients.
Not only did we hold a press conference and showcase our knowledge and experience with COVID-19 and hydroxychloroquine, but we also presented significant evidence of its safety and efficacy.— Dr. Simone Gold (@drsimonegold) July 30, 2020
Social media companies censored & removed it all. Why? pic.twitter.com/C14EvHL48W
Doubling Down in Ohio
Meanwhile the Ohio Board of Pharmacy has banned the dispensing of hydroxychloroquine for the treatment or prevention of COVID-19 from today.
The rule prohibits pharmacies from selling or dispensing hydroxychloroquine and chloroquine for use as a coronavirus treatment without approval from the board’s executive director. It also specifies that all prior approvals for the drugs are no longer applicable.
The rule reads:
4729:5-5-21 Prescription requirements for chloroquine and hydroxychloroquine.
(A) No prescription for chloroquine or hydroxychloroquine may be dispensed by a pharmacist or sold at retail by a licensed terminal distributor of dangerous drugs, including prescriptions for patients residing in Ohio dispensed or sold at retail by nonresident terminal
distributors of dangerous drugs as defined in rule 4729:5-8-01 of the Administrative Code, unless the prescription bears a written diagnosis code from the prescriber or a statement indicating its veterinary medical purpose.
(B) Except as provided in paragraph (C) of this rule, prescriptions issued for chloroquine or hydroxychloroquine for prophylactic use related to COVID-19 or for the treatment of COVID19 are strictly prohibited unless otherwise approved by the board’s executive director in consultation with the board president, at which time a resolution shall issue. Upon the
effective date of this rule, all previous approvals for the use of chloroquine or hydroxychloroquine shall be deemed void and must be approved using the process outlined in this paragraph.
(C) The prohibition in paragraph (B) of this rule does not apply to prescriptions issued as part of a documented institutional review board-approved clinical trial to evaluate the safety and efficacy of the drugs to treat COVID-19. Prescriptions must include documentation that
the patient is enrolled in a clinical trial.
(D) Paragraphs (B) and (C) of this rule shall also apply to medication orders and outpatient prescriptions dispensed by institutional pharmacies as defined in agency 4729 of the Administrative Code.
REMINDER: Based on ongoing analysis and emerging scientific data, FDA has revoked the emergency use authorization (EUA) to use hydroxychloroquine and chloroquine to treat COVID-19 in certain hospitalized patients when a clinical trial is unavailable or participation is not feasible. The agency made this determination based on recent results from a large, randomized clinical trial in hospitalized patients that found these medicines showed no benefit for decreasing the likelihood of death or speeding recovery.
OHIO BOARD OF PHARMACY
Basically, the state of Ohio just told its 30,000 physicians that patients can’t trust them to make the right decisions. This is a direct infringement on the patient-doctor relationship.